Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis
Yun Su, Tongze Cai, Jingxuan Wei, Qiuju Huang, Chun Yao, Lei Fu, Jinghui Zheng, Hongwei Guo, Xiongbin Gui · 2026
Read Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis by Yun Su, Tongze Cai, Jingxuan Wei, Qiuju Huang, Chun Yao, Lei Fu, Jinghui Zheng, Hongwei Guo, Xiongbin Gui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13279430.txt.
Description
Yun Su and colleagues published a 2026 Bayesian network meta-analysis ranking first-line treatments for advanced hepatocellular carcinoma, the dominant form of liver cancer. Since sorafenib became the long-standing standard, combination regimens have multiplied, yet few were tested directly against each other. The team pooled sixteen phase III randomized trials with 8,753 patients, comparing survival, time before the cancer progressed, and severe side effects through a network linking treatments via shared comparators.
Regimens built around hepatic arterial infusion chemotherapy, which delivers drugs straight into the liver's blood supply, ranked highest for both progression-free and overall survival. Several immunotherapy combinations also improved survival across patient subgroups without a matching rise in severe side effects. The authors note that rankings from indirect evidence depend heavily on which comparators the trials used. They call for direct head-to-head trials and updated analyses as the evidence base keeps shifting.
Catalog record
| CREATOR | Yun Su, Tongze Cai, Jingxuan Wei, Qiuju Huang, Chun Yao, Lei Fu, Jinghui Zheng, Hongwei Guo, Xiongbin Gui |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |